6-(2-methoxyphenyl)pyridin-3-amine | 1225523-05-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(2-methoxyphenyl)pyridin-3-amine
• CAS: 1225523-05-6
• 化学式: C₁₂H₁₂N₂O
• 分子量: 200.24
• InChiKey: CXBJHUCVRRPSNQ-UHFFFAOYSA-N

物化性质

• 沸点：
  339.3±27.0 °C(Predicted)
• 密度：
  1.149±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  48.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(2-methoxyphenyl)pyridin-3-amine 在 N,N-二异丙基乙胺 作用下， 以 丙醇 、 乙二醇 为溶剂， 反应 4.0h， 生成 N²-(4-aminocyclohexyl)-9-cyclopentyl-N⁶-(6-(2-methoxyphenyl)pyridin-3-yl)-9H-purine-2,6-diamine
  参考文献：
  名称：

  Activity of 2,6,9-trisubstituted purines as potent PDGFRα kinase inhibitors with antileukaemic activity

  摘要：

  Receptor tyrosine kinase PDGFR alpha is often constitutively activated in various tumours and is regarded as a drug target. Here, we present a collection of 2,6,9-trisubstituted purines with nanomolar potency against PDGFR alpha and strong and selective cytotoxicity in the human eosinophilic leukaemia cell line EOL-1 that expresses the FIP1L1-PDGFRA oncogene. In treated EOL-1 cells, the example compound 14q inhibited the autophosphorylation of PDGFR alpha and the phosphorylation of STAT3 and ERK1/2. Interestingly, we observed pronounced and even increased effects of 14q on PDGFR alpha and some of its downstream signalling pathways after drug washout. In accordance with suppressed PDGFR alpha signalling, treated cells were arrested in the G1 phase of the cell cycle and eventually underwent apoptosis. Our results show that substituted purines can be used as specific modulators of eosinophilic leukaemia. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.111663
• 作为产物：
  描述：

  2-溴-5-硝基吡啶 在 potassium phosphate monohydrate 、 5%-palladium/activated carbon 、 四丁基溴化铵 、 氢气 、 palladium diacetate 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 80.0 ℃ 、101.33 kPa 条件下， 反应 4.0h， 生成 6-(2-methoxyphenyl)pyridin-3-amine
  参考文献：
  名称：

  Activity of 2,6,9-trisubstituted purines as potent PDGFRα kinase inhibitors with antileukaemic activity

  摘要：

  Receptor tyrosine kinase PDGFR alpha is often constitutively activated in various tumours and is regarded as a drug target. Here, we present a collection of 2,6,9-trisubstituted purines with nanomolar potency against PDGFR alpha and strong and selective cytotoxicity in the human eosinophilic leukaemia cell line EOL-1 that expresses the FIP1L1-PDGFRA oncogene. In treated EOL-1 cells, the example compound 14q inhibited the autophosphorylation of PDGFR alpha and the phosphorylation of STAT3 and ERK1/2. Interestingly, we observed pronounced and even increased effects of 14q on PDGFR alpha and some of its downstream signalling pathways after drug washout. In accordance with suppressed PDGFR alpha signalling, treated cells were arrested in the G1 phase of the cell cycle and eventually underwent apoptosis. Our results show that substituted purines can be used as specific modulators of eosinophilic leukaemia. (C) 2019 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2019.111663

文献信息

• Agent for Treatment of Eye Diseases
  申请人：Kakizuka Akira

  公开号：US20140148416A1

  公开（公告）日：2014-05-29

  The present invention provides agents effective to treat eye diseases, pharmaceutical compositions comprising them, methods for preparing pharmaceuticals for treatment of eye diseases comprising using the agents, use of the agents in manufacture of pharmaceuticals for treatment of eye diseases and methods for treating eye diseases comprising administering the agents or the pharmaceutical compositions. The eye diseases treated by the present invention include particularly glaucoma, especially normal tension glaucoma, or retinitis pigmentosa. The present invention provides the compound of formula (I) wherein R is as defined in the description.

  本发明提供了治疗眼部疾病的有效药剂，包括它们的制药组合物，制备用于治疗眼部疾病的药物的方法，包括使用这些药剂，以及在制造用于治疗眼部疾病的药物时使用这些药剂的方法，以及通过给药这些药剂或药物组合物来治疗眼部疾病的方法。本发明治疗的眼部疾病包括青光眼，特别是正常张力青光眼，或色素性视网膜病变。本发明提供了式（I）的化合物，其中R在说明中定义。
• Naphthalene Derivative
  申请人：Kakizuka Akira

  公开号：US20130184241A1

  公开（公告）日：2013-07-18

  The present invention provides compounds which can regulate VCP activity. The present invention provides the compound of formula (I) (R is as defined in the description) or oxides, esters, prodrugs, pharmaceutically acceptable salts or solvates thereof. The compounds can regulate VCP activity, and thus are useful for treating VCP-mediated diseases such as neurodegenerative diseases.

  本发明提供了可以调节VCP活性的化合物。本发明提供了式(I)的化合物（其中R如描述中所定义）或其氧化物、酯、前药、药学上可接受的盐或溶剂。这些化合物可以调节VCP活性，因此可用于治疗VCP介导的疾病，如神经退行性疾病。
• [EN] TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS<br/>[FR] TRAITEMENT DE CANCERS ENTRAÎNÉS PAR MYC AVEC DES AGENTS DE DÉGRADATION GSPT1
  申请人：MONTE ROSA THERAPEUTICS AG

  公开号：WO2022152822A1

  公开（公告）日：2022-07-21

  The present disclosure relates to new methods to predict the responsiveness of cancer patients to GSPT1 negative modulators and thus determine the of efficacy GSPT1 negative modulators to treat cancer patients by determining the level of one or more biomarkers in samples of the patients. The present disclosure also relates to applications of these methods, which includes stratifying cancer malignancies, in particular identifying myc-driven cancers, and thereby devising optimized and personalized treatments for these cancer patients, as well as optimizing the selection of patient populations for respective clinical trials.

  本公开涉及新的方法来预测癌症患者对GSPT1负调节剂的反应性，从而通过确定患者样本中一个或多个生物标志物的水平来确定GSPT1负调节剂治疗癌症患者的有效性。本公开还涉及这些方法的应用，包括分层癌症恶性程度，特别是识别驱动肿瘤的myc，从而为这些癌症患者设计优化和个性化的治疗方案，以及优化选择患者人群进行相应的临床试验。
• [EN] ISOINDOLINONE COMPOUNDS<br/>[FR] COMPOSÉS D'ISOINDOLINONE
  申请人：MONTE ROSA THERAPEUTICS AG

  公开号：WO2022152821A1

  公开（公告）日：2022-07-21

  Disclosed herein are compound or pharmaceutically acceptable salts or stereoisomers thereof of formula (I). These compounds find use as modulators of cereblon, in particular in the treatment of abnormal cell growth in mammals, especially humans.

  本文揭示了公式(I)的化合物或药学上可接受的盐或其立体异构体。这些化合物可用作 cereblon 调节剂，特别是用于治疗哺乳动物，尤其是人类的异常细胞生长。
• [EN] PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES DESTINÉES À ÊTRE UTILISÉES POUR PRÉVENIR OU TRAITER UNE MALADIE OU UN TROUBLE PROVOQUÉ PAR OU ASSOCIÉ À UN OU PLUSIEURS CODONS DE TERMINAISON PRÉMATURÉS
  申请人：MONTE ROSA THERAPEUTICS AG

  公开号：WO2022200857A1

  公开（公告）日：2022-09-29

  The present disclosure relates to a. compound of formula I or a. pharmaceutically acceptable salt thereof Formula I wherein A is Formula II X1is linear or branched C1-6alkyl, C3-6cycloalkyl, C6-10aryl, 5-10 membered heteroaryl, 4-8 membered heterocycloalkyl, wherein X1is unsubstituted or substituted with one or more of halogen, linear or branched C1-6alkyl, linear or branched C1-6heteroalkyl, CF3, CHF2, CMeF2, -O-CHF2, -O-(CH2)2-OMe, OCF3, C1-6alkylamino, -CN, -N(H)C(O)-C1-6alkyl, - OC(O)-C1-6alkyl, -OC(O)-C1-4alkylamino, -C(O)O-C1-6alkyl, -COOH, -CHO, -C1-6alkylC(O)OH, -C1-6alkylC(O)O-C1-6alkyl, NH2, C1-6alkoxy or Cue alkylhydroxy; or X1together with X4forms a 4-8 membered heterocycloalkyl, which is unsubstituted or substituted with one or more of halogen, linear or branched -C1-6alkyl, CF3, CHF2, CMeF2, -O-(CH2)2-OMe, OCF3, OCHF2, C1-6alkylamino, -CN, -N(H)C(O)-C1-6alkyl, -OC(O)-C1-6alkyl, -C(O)O-C1-6alkyl, -COOH, -C1-6alkylC(O)OH, -C1-6alkylC(O)O-C1-6alkyl, NH2, C1-4alkylhydroxy, or C1-4alkoxy; X2is hydrogen, C3-6cycloalkyl, C6-10aryl, 5-10 membered heteroaryl, 4-8 membered heterocycloalkyl, wherein X2is unsubstituted or substituted with one or more of linear or branched Cue alkyl, -C1-4alkoxy, NH2, NMe2, halogen, CF3, CHF2, CMeF2, -O-(CH2)2-OMe, OCF3, OCHF2, CM alkylhydroxy, X3is -NH-, -O-; X4is -NH-, - CH2-; L1is a covalent bond, C1-6alkyl, which is unsubstituted or substituted with one or more of C1-4alkyl, halogen; L2is a covalent bond, Cue alkyl, which is unsubstituted or substituted with one or more of CM alkyl, halogen; L3is a covalent bond, -O-, - C1-4alkoxy or C1-6alkyl, which is unsubstituted or substituted with one or more of C1-4alkyd, halogen, for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons in a monotherapy or in a combined therapy with an aminoglycoside or a. pharmaceutically acceptable salt thereof.

  本公开涉及式I的化合物或其药学上可接受的盐，其中A为式II，X1为线性或支链C1-6烷基，C3-6环烷基，C6-10芳基，5-10成员杂芳基，4-8成员杂环烷基，其中X1未取代或取代有卤素，线性或支链C1-6烷基，线性或支链C1-6杂烷基，CF3，CHF2，CMeF2，-O-CHF2，-O-(CH2)2-OMe，OCF3，C1-6烷基氨基，-CN，-N(H)C(O)-C1-6烷基，-OC(O)-C1-6烷基，-OC(O)-C1-4烷基氨基，-C(O)O-C1-6烷基，-COOH，-CHO，-C1-6烷基C(O)OH，-C1-6烷基C(O)O-C1-6烷基，NH2，C1-6烷氧基或Cue烷基羟基；或X1与X4共同形成未取代或取代有卤素，线性或支链C1-6烷基，CF3，CHF2，CMeF2，-O-(CH2)2-OMe，OCF3，OCHF2，C1-6烷基氨基，-CN，-N(H)C(O)-C1-6烷基，-OC(O)-C1-6烷基，-C(O)O-C1-6烷基，-COOH，-C1-6烷基C(O)OH，-C1-6烷基C(O)O-C1-6烷基，NH2，C1-4烷基羟基或C1-4烷氧基的4-8成员杂环烷基；X2为氢，C3-6环烷基，C6-10芳基，5-10成员杂芳基，4-8成员杂环烷基，其中X2未取代或取代有线性或支链Cue烷基，-C1-4烷氧基，NH2，NMe2，卤素，CF3，CHF2，CMeF2，-O-(CH2)2-OMe，OCF3，OCHF2，CM烷基羟基，X3为-NH-，-O-；X4为-NH-，-CH2-；L1为共价键，C1-6烷基，未取代或取代有C1-4烷基，卤素；L2为共价键，Cue烷基，未取代或取代有CM烷基，卤素；L3为共价键，-O-，-C1-4烷氧基或C1-6烷基，未取代或取代有C1-4烷基，卤素，用于单一疗法或与氨基糖苷类药物或其药学上可接受的盐联合疗法预防和治疗由一个或多个过早终止密码子引起或相关的疾病或障碍。